Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Mistry is a seasoned finance professional having an extensive work experience spanning more than 25 years
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Genomics is transforming the future of modern medicine and treatment modalities across specialties
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
Mantri will replace V. S. Mani, Executive Director & Global Chief Financial Officer of the company as he has conveyed his decision to opt for early retirement
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
Subscribe To Our Newsletter & Stay Updated
